News & Media

SK life science

Welcome to the news and information center for SK Life Science, Inc. (SKLSI), a CNS-focused pharmaceutical company

Here you will find the latest announcements and contact information for SK life science.

For media inquiries, please contact .

General business

Strategic alliance and partnership opportunities

Media inquiries and PR

Grant and investigator initiated proposals

Sponsorship requests

Medical information inquiries or report adverse events

SK life science at a glance

  • Headquarters location

    PARAMUS, NJ

  • R&D Begins

    1993

  • Parent Company

    SK life science is a subsidiary of SK Biopharmaceuticals, Co., Ltd., and both are part of the SK Group

  • Number of employees

    200+ EMPLOYEES

  • Disease Category Focus

    CNS

  • Pipeline

    8 compounds under clinical development

Newsroom

SK life science Presents Long-term Data on Cognitive and Psychiatric Adverse Events Associated with XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AAN 2022 Annual Meeting

Full release

SK life science to Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Academy of Neurology 2022 Annual Meeting

Full release

SK Biopharmaceuticals Becomes First Korean Company to Join Pharmaceutical Supply Chain Initiative

Full release

SK life science Announces FDA Clearance of IND Application for its Oncology Candidate, SKL27969, a PRMT5 Inhibitor for the Potential Treatment of Advanced Solid Tumors

Full release

SK life science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome

Full release

SK Biopharmaceuticals Enters into Licensing Agreement with Endo for Cenobamate in Canada

Full release

SK life science Presents Long-Term Data of XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset Seizures at the American Epilepsy Society 2021 Annual Meeting

Full release

SK life science To Present Latest XCOPRI® (cenobamate tablets) CV Data at the American Epilepsy Society 2021 Annual Meeting

Full release

SK Biopharmaceuticals Enters Greater China Out-Licensing 6 Clinical Pipelines to CNS-Focused Biotech Ignis Therapeutics

Full release

Epilepsia Publishes Two Post-hoc Analyses from Long-Term Study of XCOPRI® (cenobamate tablets) CV

Full release